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Background
Chronic obstructive pulmonary disease (COPD) is a
complex disorder associated with significant cardiovas-
cular morbidity and mortality. Despite this, current car-
diovascular scoring systems do not include COPD in
their risk prediction models. The aims of this case- con-
trol study were to assess whether differences in cardio-
vascular surrogate markers exist in COPD to further
understand the relationship of COPD to cardiovascular
structure and function.
Methods
We performed a post-hoc cross-sectional analysis utilising
baseline data from two randomized controlled trials (n =
36 and 54). 26 COPD patients with lung hyperinflation
were matched for global cardiovascular risk, using the UK
population validated QRISK2 score, with 26 controls with
normal lung function. Patients underwent 1.5T cardiac
magnetic resonance imaging, non-invasive arterial stiffness
assessment and lung function testing.
Results
Cardiac chamber size and stroke volume was decreased in
COPD patients with lung hyperinflation compared to con-
trols matched for cardiovascular risk. The mean differ-
ences in left ventricle stroke volume index (LVSVI), left
and right ventricular end diastolic volume index were
-10.3 ml/m2 (95% CI -15.1, -5.5, p < 0.001), -14.1 ml/m2
(95% CI -21.9,-6.3 p < 0.001) and -13.0 ml/m2 (95% CI
-23.3, -2.6 P < 0.015) respectively, which were shown to be
associated with airflow limitation in multivariate models.
Pulse wave velocity (PWV) (mean difference +1.0 m/s,
95% CI 0.02-1.92; p = 0.045) and total arterial compli-
ance (TAC) (mean difference -0.27 mL/m2/mmHg, 95%
CI -0.39, -0.15; p < 0.001) were adversely affected in
COPD compared to the control group. In the whole
cohort (n = 90) QRISK2 (b= 0.046, p = 0.017) and FEV1
(b=-0.013, p = 0.022) were associated with PWV in mul-
tivariate analysis. The relationship between QRISK2 and
PWV appeared to be modified by COPD, where the
interaction term reached borderline significance (p =
0.060). FEV1 (b=0.005, p = 0.004) was also associated
with TAC in multivariate analysis.
Conclusions
Surrogate markers for cardiovascular outcomes are
adversely affected in COPD compared to a group
matched for global cardiovascular risk with normal lung
function. Our findings suggesting that current scoring
systems may be suboptimal for cardiovascular risk pre-
diction in COPD.
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Figure 1 Differences in PWV, TAC and their relationship to QRISK2 in COPD compared to controls matched for cardiovascular risk.
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